Navigation Links
Advanced Life Sciences Featured as Special Stock Pick by KonLin Investment Letter
Date:8/5/2010

span class="xn-money">$1.00."
  • "Unbelievably, antibiotic resistant bacteria are responsible for more deaths each year in the U.S. than HIV/AIDS. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CABP, Restanza™ has shown effectiveness against pathogens that represent Global Public Health and Bioterror threats. As resistance to the first-line treatments grows, there is a medical need for new therapeutics that works differently than existing agents to treat anthrax infection. The FDA has granted Orphan Drug Designation to Restanza™ for the prophylactic treatment of anthrax, plague and tularemia."

    • About Advanced Life Sciences

    Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza™, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including community acquired bacterial pneumonia (CABP) and biodefense pathogens including anthrax, plague and tularemia.  In June 2010, the Company submitted a Special Protocol Assessment (SPA) with the FDA for the proposed Phase III clinical program of Restanza in the treatment of patients with CABP. The Company has been engaged in the SPA process with the FDA over the last year to establish the clinical trial design needed to gain approval in CABP. As filed, the updated SPA incorporates written and oral comments from the FDA's Division of Anti-Infective and Ophthalmology Products.  Based on the FDA's review cycle, the Company expects a reply to its submission by mid-August of this year.


    '/>"/>
    SOURCE Advanced Life Sciences Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4

    Related medicine technology :

    1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
    3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
    5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
    6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
    7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
    8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
    9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
    11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 ... Inc. (NASDAQ: REGN) today announced that the New ... Phase 2a study results of dupilumab (SAR231893/REGN668) in patients ... antibody targeting the alpha subunit of the interleukin 4 ... and IL-13, drivers of Th2 (Type 2 helper T ...
    (Date:5/21/2013)... , May 21, 2013 Abaxis, Inc. (NasdaqGS: ... systems, announced today that Martin Mulroy ... Stifel Annual Dental & Veterinary Conference on Wednesday, May ... be held at Le Parker Meridien Hotel in ... Abaxis Abaxis develops, manufactures, markets and sells ...
    (Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Medical Devices in the US Market ... Changing Regulatory and Reimbursement Scenario for ...   Summary ...
    Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
    ... 10, 2011 Sanofi-aventis (EURONEXT: SAN and ... (Nasdaq: REGN ) today announced results from ... aflibercept (VEGF Trap) for the second-line treatment of non-small ... aflibercept to the chemotherapy drug docetaxel did not meet ...
    ... 2011 Transgenomic, Inc. (OTC Bulletin Board: TBIO ) ... December 31, 2010, and provided a business update. The ... $0.06 per share, compared with a net loss for 2009 of ... $20.0 million, compared with $22.0 million for 2009.  Gross profit was ...
    Cached Medicine Technology:Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 2Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 3Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 4Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 5Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 6Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer 7Transgenomic Reports Fourth Quarter Financial Results 2Transgenomic Reports Fourth Quarter Financial Results 3Transgenomic Reports Fourth Quarter Financial Results 4Transgenomic Reports Fourth Quarter Financial Results 5Transgenomic Reports Fourth Quarter Financial Results 6Transgenomic Reports Fourth Quarter Financial Results 7
    (Date:5/21/2013)... 21, 2013 According to a May 13, ... Use of Botox,” Botox injections have become the ... in 2002 (Go to goo.gl/8iYbD). Although it is mostly associated ... men. The injection makes facial wrinkles less visible by paralyzing ... for about three months. This means that people who are ...
    (Date:5/21/2013)... Diversity Focus, a non-profit organization striving to ... in the Creative Corridor region, is releasing results for ... conference on Thursday, May 23rd at 10:30 a.m. ... , The survey is a critical component ... that attract, nurture and retain people of diverse backgrounds, ...
    (Date:5/21/2013)... (May 21, 2013) A paper recently published in ... co-written by physicians and scientists at the University of ... risk factor for pulmonary fibrosis can be used to ... , Researchers looked at a fairly common variant of ... component of the mucous produced by the bronchial tubes. ...
    (Date:5/21/2013)... for scientific and technological research So Paulo Research Foundation, ... an investment estimated in US$ 680 million to support ... period of up to eleven years, subject to continuation ... Funding for the 17 RIDCs will come from FAPESP ... personnel, and infrastructure). Host institutions will participate in a ...
    (Date:5/21/2013)... Park City, Utah (PRWEB) May 21, 2013 ... on HRA, HSA and FSA accounts. Zane ... employer sponsored health benefits, is the leader in ... health reimbursement arrangements . , According to Zane ... or health reform) was signed into law in 2010 ...
    Breaking Medicine News(10 mins):Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2Health News:Research at the cutting edge of knowledge 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 2Health News:Zane Benefits Publishes New Information on HRA, HSA and FSA Accounts 3
    ... brain,s dopamine levels could point to more effective treatments ... -- Long-term changes in the brain,s dopamine-releasing machinery may ... say. , Dopamine is one of the brain,s major ... Bamford, of the University of Washington, Seattle, treated mice ...
    ... Skin Care and Frida,Kahlo Store are proud to announce the ... benefit of The Leukemia & Lymphoma Society. It,will take place ... Staten Island, New York, at 7:30 pm. This concert is ... with the solution,of health and social problems., The event ...
    ... leading global clinical,research organization, is pleased to announce that ... with CRO,s in Las Vegas, Nevada from April,14 to ... by,some of its executive team and employees. Chiltern will ... 2008 at 2:45 pm -- Track: Relationship Management ...
    ... to use iSEEK Medical Searchblade to optimize patient management ... ... 9 Physicians, nurses,physician assistants, pharmacists, and other clinicians searching for,medical ... Thanks to a new partnership between MedPage Today and iSEEK,the medical ...
    ... Peninsula Medical School, South West England, has found strong ... health of older people. , Two studies were conducted, ... Study of Ageing (ELSA). , The first study ... lived in urban areas across England. The study found ...
    ... April 9, 2008 Reflecting the,growing concern over ... in being able to afford a comfortable retirement,decreased ... in the 18 years of the,Retirement Confidence Survey(R)(RCS), ... of workers very confident about having enough money ...
    Cached Medicine News:Health News:Researchers Define Mechanism of Methamphetamine Addiction 2Health News:Chiltern Will Sponsor and Present at the 17th Annual Partnerships With CRO's Meeting in Las Vegas, April 14 - 16, 2008. 2Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 2Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 3Health News:MedPage Today(R) Selects iSEEK(TM) to Improve Quality of Patient Care 4Health News:Your neighborhood can affect your health 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 2Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 3Health News:18th Annual Retirement Confidence Survey:(R) Workers Show Record Drop in Retirement Confidence, Health Care and Economy Are Major Concerns 4
    Inquire...
    Remote Blower With Bag-In/Bag-Out Option...
    Class II Type B2 Biological Safety Cabinet...
    Class II Type A2 Biological Safety Cabinet...
    Medicine Products: